darbepoetin alfa inn dɑːrbəˈpoʊɪtɪn reengineered form erythropoietin containing amino acid changes resulting creation new sites nlinked carbohydrate addition longer serum halflife compared epoetin alpha epoetin beta stimulates erythropoiesis increases red blood cell levels mechanism rhuepo binding activating epo receptor used treat anemia commonly associated chronic kidney failure cancer chemotherapy darbepoetin marketed amgen trade name aranesp medication approved september us food drug administration treatment anemia patients chronic kidney failure intravenous subcutaneous june approved european medicines agency indication well treatment anemia cancer patients undergoing dr reddys laboratories launched darbepoetin alfa india brand name cresp august worlds first followon biologic darbepoetin alfa darbepoetin produced recombinant dna technology modified chinese hamster ovary differs endogenous erythropoietin epo containing two nlinked oligosaccharide chains erythropoiesisstimulating acid protein world health organizations list essential use darbepoetin alfa contraindicated patients hypersensitivity drug preexisting uncontrolled hypertension pure red cell darbepoetin alfa black box warnings united states increased risk death myocardial infarction stroke venous thromboembolism thrombosis vascular access tumor progression recurrence avoid side effects recommended patients chronic kidney failure cancer use lowest possible dose needed avoid red blood cell rbc addition listed black box warning use darbepoetin alfa also increases risk cardiovascular problems including cardiac arrest arrhythmia hypertension congestive heart failure recent study extended findings treatment patients exhibiting cancerrelated anemia distinct anemia resulting citation needed reported adverse reactions include increased risk seizure hypotension chest paincitation needed darbepoetin alfa assigned pregnancy category united known darbepoetin alfa excreted breast darbepoetin alfa binds erythropoietin receptor erythroid progenitor cells stimulating rbc production amgen sent dear stockholders letter january highlighted results recent anemia cancer trial warned doctors consider use offlabel indication amgen advised us food drug administration fda results dahanca clinical trial dahanca data monitoring committee found locoregional control subjects treated aranesp significantly worse receiving aranesp needed response advisories fda released public health march clinical doctors february use erythropoeisisstimulating agents esas epoetin alfa marketed epogen darbepoetin alfa advisory recommended caution using agents cancer patients receiving chemotherapy chemotherapy indicated lack clinical evidence support improvements quality life transfusion requirements settings according update clinical practice guidelines american society clinical oncology asco american society hematology ash use esas darbepoetin alfa cancer patients appropriate following stipulations outlined fdaapproved like epo darbepoetin alfa potential abused athletes seeking competitive advantage use winter olympic games improve performance led disqualification crosscountry skiers larisa lazutina russia olga danilova russia johann mühlegg spain final epogen aranesp billion combined sales procrit sales billion link httpsenwikipediaorgwikidarbepoetinalfa